With these distinctive capacities, TLR3-preconditioned UC-MSC showed improved therapeutic efficacy against experimental animal models for autoimmune diseases, especially on inflammatory bowel disease (IBD) [31]. This evidence concerns the gene TLR3 and inflammatory bowel disease.